J&J, Angiotech Reach Accord Over Stent Patents

Law360, New York (September 17, 2007, 12:00 AM EDT) -- Johnson & Johnson subsidiary Conor Medsystems has reached a settlement with Angiotech Pharmaceuticals Inc. to resolve litigation regarding drug-eluting stents used in cancer chemotherapy.

Vancouver, Canada-based Angiotech announced the “favourable” agreement on Monday on all outstanding patent litigation with respect to Conor's CoStar paclitaxel stent. Terms of the settlement, which resolved litigation in the U.K., the Netherlands and Australia, were not disclosed.

"With this agreement now in place, Angiotech expects that the resources required to defend and enforce our intellectual property should decrease," said Dr. William...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.